
**Claims**

1. Use of an IL-8 inhibitor in the manufacture of a medicament for the treatment and/or prevention of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) and benign prostatic hyperplasia.

2. The use of claim 1 wherein the IL-8 inhibitor is a CXCR1 inhibitor or a dual CXCR1 and CXCR2 inhibitor.

3. The use of claim 1 or claim 2 wherein the IL8 inhibitor is selected from a small molecule, antibody or peptide.

4. The use of any one of claims 1 to 3 wherein the IL-8 inhibitor is a compound having formula (I)




(I)

or a pharmaceutically acceptable salt thereof,

wherein

R1 is hydrogen;

X is OH;


R2 is hydrogen or linear $C_1$-$C_4$ alkyl;

Y is a heteroatom selected from S, O and N;

Z is selected from linear or branched $C_1$-$C_4$ alkyl, linear or branched $C_1$-$C_4$ alkoxy, halo $C_1$-$C_3$ alkyl and halo $C_1$-$C_3$ alkoxy.

5. The use of any one of claims 1 to 4 wherein the IL-8 inhibitor is selected from (R,S)-2-(4-{[4-(trifluoromethyl)-1,3-thiazol-2-yl]amino}phenyl)propanoic acid and (2S)-2-(4-{[4-(trifluoromethyl)-1,3-thiazol-2-yl] amino} phenyl) propanoic acid, preferably as sodium salt.

6. The use of any one of claims 1 to 3 wherein the IL-8 inhibitor is a compound having formula (II)



(II)

or a pharmaceutically acceptable salt thereof,

wherein

R' is hydrogen;

R is a residue of formula $SO_2Ra$ wherein Ra is linear or branched $C_1$-$C_4$ alkyl or halo $C_1$-$C_3$ alkyl.

7. The use of any one of claims 1 to 3 and 6 wherein the IL-8 inhibitor is R(-)-2-[(4'-trifluoromethanesulfonyloxy)phenyl]-N-methanesulfonyl propionamide, preferably the sodium salt thereof.


8. Use of a pharmaceutical composition comprising an IL-8 inhibitor in the manufacture of a medicament for the treatment and/or prevention of chronic

prostatitis/chronic pelvic pain syndrome (CP/CPPS) and benign prostatic hyperplasia, wherein the IL-8 inhibitor is:

a) a CXCR1 inhibitor or a dual CXCR1 and CXCR2 inhibitor;

b) selected from a small molecule, antibody or peptide;

c) a compound having formula (I)




(I)

or a pharmaceutically acceptable salt thereof,

wherein

R1 is hydrogen;

X is OH;


R2 is hydrogen or linear $C_1$-$C_4$ alkyl;

Y is a heteroatom selected from S, O and N;

Z is selected from linear or branched $C_1$-$C_4$ alkyl, linear or branched $C_1$-$C_4$ alkoxy, halo $C_1$-$C_3$ alkyl and halo $C_1$-$C_3$ alkoxy;

d) selected from (R,S)-2-(4-{[4-(trifluoromethyl)-1,3-thiazol-2-yl]amino}phenyl)propanoic acid and (2S)-2-(4-{[4-(trifluoromethyl)-1,3-thiazol-2-yl] amino} phenyl) propanoic acid, preferably as sodium salt;

e) a compound having formula (II)




(II)

or a pharmaceutically acceptable salt thereof,

wherein

R' is hydrogen;

R is a residue of formula $SO_2Ra$ wherein Ra is linear or branched $C_1$-$C_4$ alkyl or halo $C_1$-$C_3$ alkyl; or

f) R(-)-2-[(4'-trifluoromethanesulfonyloxy)phenyl]-N-methanesulfonyl propionamide, preferably the sodium salt thereof.

9. The use of claim 8 wherein the pharmaceutical composition further comprises at least one further pharmaceutically active compound.

10. Use of a product or a kit comprising:

A) the medicament of any one of claims 1 to 9, and

B) at least one further pharmaceutically active compound

A) and B) being two separate formulations for simultaneous, separate or sequential use, in the manufacture of a medicament for the treatment and/or prevention of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) and benign prostatic hyperplasia.

11. The use of claim 9 or claim 10 wherein said further pharmaceutically active compound is an active compound useful for the prevention and treatment of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) and benign prostatic hyperplasia.

12. The use of claim 11, wherein said further pharmaceutically active compound is selected from antibiotics, anti-inflammatory agents, alpha-blockers and 5-alpha reductase inhibitors.